Faculty Collaboration Database

Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. Br J Haematol 2007 Mar;136(5):752-61

Date

02/23/2007

Pubmed ID

17313378

DOI

10.1111/j.1365-2141.2007.06498.x

Scopus ID

2-s2.0-33846959836 (requires institutional sign-in at Scopus site)   21 Citations

Abstract

A total of 143 patients with relapsed (n = 90), primary refractory (n = 32) and first line chemotherapy responsive (n = 21) non-Hodgkin lymphoma (NHL) and Hodgkin disease (HD) were treated with IVE (ifosphamide, etoposide and epirubicin) chemotherapy with the intent to proceed to high-dose therapy with either autologous or allogeneic transplantation, following peripheral blood stem cell mobilisation. A major response (complete/partial response) to IVE was seen in 115 patients (80.4%) with 5-year overall survival (OS) and event free survival (EFS) of 53% and 43%, respectively. Subgroup analysis showed overall response rates of 93.1% for HD with a 5-year OS and EFS of 62% and 52% respectively, while NHL showed response rates of 78.0% with 5-year OS and EFS of 50% and 39% respectively. The median number of CD34 +ve cells mobilised following IVE was 7.86 x 10(6) (range 1.72-42.91 x 10(6)), with 60% mobilising >2 x 10(6)/kg in a single collection. Grade IV neutropenia was seen in 79.6% patients and 77/270 cycles required intravenous antibiotic treatment. We conclude that IVE has a high response rate across a range of refractory and relapsed lymphoma with acceptable toxicity and excellent PBSC mobilising characteristics.

Author List

Bishton MJ, Lush RJ, Byrne JL, Russell NH, Shaw BE, Haynes AP

Author

Bronwen E. Shaw MBChB, PhD Center Director, Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Epirubicin
Etoposide
Female
Hematopoietic Stem Cell Mobilization
Hodgkin Disease
Humans
Ifosfamide
Lymphoma, Non-Hodgkin
Male
Middle Aged
Neutropenia
Peripheral Blood Stem Cell Transplantation
Salvage Therapy
Survival Analysis
Treatment Outcome